Krystal Biotech (KRYS)

• Market cap: $5.41B
• 1 day: 2.87%
• 5 days: 19.82%
• 1 month: 23.96%
• 3 months: 3.06%
• 6 months: -6.83%
• Year to date: 20.04%
• 1 year: 73.93%
• 5 years: 216.90%
• 10 years: 1,665.60%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Employees: 275

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

72% more call options, than puts

Call options by funds: $63.3M | Put options by funds: $36.8M

4% less repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 95

4.33% less ownership

Funds ownership: 97.91% [Q3] → 93.58% (-4.33%) [Q4]

8% less funds holding

Funds holding: 278 [Q3] → 255 (-23) [Q4]

17% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 5 (-1) [Q4]

18% less capital invested

Capital invested by funds: $5.12B [Q3] → $4.22B (-$903M) [Q4]

28% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 50

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $215 14% upside
• Avg. target: $217 16% upside
• High target: $221 18% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Citigroup Yigal Nochomovitz 33% 1-year accuracy 14 / 43 met price target	14% upside $215	Neutral Maintained	20 Feb 2025
Cantor Fitzgerald Josh Schimmer 29% 1-year accuracy 17 / 59 met price target	14% upside $215	Overweight Reiterated	20 Feb 2025
Chardan Capital Geulah Livshits 14% 1-year accuracy 7 / 51 met price target	16% upside $218	Buy Maintained	20 Feb 2025
HC Wainwright & Co. Joseph Pantginis 23% 1-year accuracy 93 / 411 met price target	18% upside $221	Buy Reiterated	19 Feb 2025